NoCode
Enzyme: A NY-based platform enabling no-code smart contract development across multiple blockchains.
Enzyme: A NY-based platform enabling no-code smart contract development across multiple blockchains.
Enzyme, founded in 2020 and headquartered in New York, is a pioneering platform focused on enabling no-code smart contract development across multiple blockchains. The company’s core mission is to democratize access to Web3 by allowing creators and businesses to develop and implement smart contracts without needing blockchain expertise. Enzyme offers services such as NFT collections, ticket sales, and free claimable tokens, all managed through user-friendly public and private dashboards. The platform aims to simplify the deployment process, requiring users only to fill out a form and click to deploy.
Notable affiliated individuals and investors have not been disclosed, but Enzyme has made significant strides in the blockchain space. Key achievements include eliminating transaction fees for publicly available smart contracts, making the platform more accessible and cost-effective. By allowing users to import and manage external public smart contracts effortlessly, Enzyme has had a substantial impact on lowering the barrier to entry for blockchain technology. This approach has empowered a broader audience to engage with and benefit from decentralized applications.
Companies similar to NoCode include Loki.code, Andromeda Protocol, Firechain and Kairos.
NoCode was founded in 2020.
NoCode's headquarters is located in New York City, NY, US.
NoCode's most recent funding round was for $120k (USD) in January 2021.
As of Jan 25, 2021, NoCode has disclosed funding of $120k (USD). Undisclosed round amounts are excluded.
NoCode has 4 employees as of Feb 4, 2024.
